Market closed

Alector/$ALEC

14:30

16:10

17:45

19:25

21:00

1D1W1MYTD1Y5YMAX

About Alector

Alector Inc is a clinical-stage biopharmaceutical company. It is engaged in developing a novel therapeutic approach for the treatment of neurodegeneration. The firm is involved in developing therapies that are designed to simultaneously counteract pathologies by restoring healthy immune function to the brain. Its pipeline products include AL001, AL002, AL003, and AL101.

Ticker

$ALEC

Sector

Health Care

Trading on

NASDAQ

Industry

Biotechnology

Headquarters

South San Francisco, United States

Employees

241

Website

www.alector.com

Alector Metrics

BasicAdvanced

$175M

-

-$1.70

0.66 -

Price and volume

Market cap

$175M

Beta

0.66

52-week high

$7.78

52-week low

$1.68

Average daily volume

1.7M

Financial strength

Current ratio

3.293

Quick ratio

3.208

Long term debt to equity

21.827

Total debt to equity

29.125

Management effectiveness

Return on assets (TTM)

-19.25%

Return on equity (TTM)

-112.55%

Valuation

Price to revenue (TTM)

2.709

Price to book

1.47

Price to tangible book (TTM)

1.47

Price to free cash flow (TTM)

-0.75

Growth

Revenue change (TTM)

-36.14%

Earnings per share change (TTM)

0.28%

3-year revenue growth (CAGR)

-32.27%

3-year earnings per share growth (CAGR)

59.43%

What the Analysts think about Alector

Analyst Ratings

Analyst ratings (Buy, Hold, Sell) for Alector stock.

Alector Financial Performance

Income Statement

Revenues and expenses

QuarterlyAnnual

Q3 24

QoQ growth

Revenue

$37B

-39.75%

Net income

$45B

107.52%

Profit margin

37.65%

6.78%

Alector Earnings Performance

Earnings per share (EPS)

Company profitability

QuarterlyAnnual

Q4 23

Q1 24

Q2 24

Q3 24

Q4 24

Actual

$3.69

$2.85

$2.45

$2.42

-

Expected

$3.55

$2.61

$2.05

$2.31

$3.94

Surprise

3.94%

9.20%

19.51%

4.63%

-

Alector News

AllArticlesVideos

Alector Reports on Recent Progress and Outlines Strategic Priorities for 2025

GlobeNewsWire·2 days ago

Neurology-Focused Alector Downgraded On Failed Alzheimer's Study, BofA Securities Highlights Lack Of Catalysts

Benzinga·1 month ago

Alector Announces Results from AL002 INVOKE-2 Phase 2 Trial in Individuals with Early Alzheimer's Disease and Provides Business Update

GlobeNewsWire·2 months ago

Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.

Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $ALEC

$

Capital at risk

Market closed

Upcoming events

No upcoming events

FAQs

What’s the current market cap for Alector stock?

Alector (ALEC) has a market cap of $175M as of January 15, 2025.

What is the P/E ratio for Alector stock?

The price to earnings (P/E) ratio for Alector (ALEC) stock is 0 as of January 15, 2025.

Does Alector stock pay dividends?

No, Alector (ALEC) stock does not pay dividends to its shareholders as of January 15, 2025.

When is the next Alector dividend payment date?

Alector (ALEC) stock does not pay dividends to its shareholders.

What is the beta indicator for Alector?

Alector (ALEC) has a beta rating of 0.66. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.